Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective.
Wei LiLi WanJiangyan Zhang
Published in: Expert review of gastroenterology & hepatology (2024)
RATIONALE 305, www.clinicaltrials.gov, identifier is NCT03777657.